Abbott, the global healthcare company, on Thursday announced the launch of XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. According to the company, XIENCE Sierra is one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases, it claimed.
“Abbott has developed several tools and devices that have improved the angioplasty procedure over the years. Percutaneous coronary intervention (PCI), also called coronary angioplasty, is a nonsurgical, minimally invasive procedure that improves blood flow to the heart. Physicians use PCI to open blood vessels to the heart that are narrowed or blocked by plaque. Often, a small mesh tube called a stent is placed to keep the artery open,” the company said in a statement.
In a press statement, the company claimed that XIENCE is one of the most-used drug-eluting stents in the world. It also claimed that XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.
“XIENCE Sierra has the same highly specialized coating that lowers the likelihood of the artery becoming re-blocked, found in other XIENCE stents. XIENCE stents collectively have an unparalleled safety record from more than 120+ clinical trials involving 120,000 patients. As per published data, the stent has proved efficacy in difficult to treat, narrowed lesions and patients with complex conditions,” it added.
“We’ve launched XIENCE Sierra in India so that physicians can smoothly deliver the stent even in challenging cases,” said Tushar Sharma, General Manager for Abbott’s vascular business in India & South Asia. “The innovative design and improved deliverability mean physicians can access and unblock difficult-to-treat lesions with more flexibility and precision. With the incidence of coronary artery disease on the rise in India, we need to provide technologies that help doctors optimally implant stents, so patients have the best outcomes possible.”
Cardiovascular diseases are the leading cause of mortality within the category of non-communicable diseases in India. Indians are also known to have a high prevalence coronary artery disease (CAD) or blockages of the arteries at 21.4 percent for patients with diabetes and 11 percent for non-diabetics. Since the first coronary angioplasty was performed in 1977 with a catheter and balloon, this technology and clinical knowledge has progressed into a lifesaving procedure in cardiovascular disease segment.
Tushar further adds, “In addition to offering next-generation stents, Abbott is helping physicians by providing technologies that enable them to implant stents most efficiently. We’ve launched AI enabled imaging tools and diagnostics to provide everything an interventional cardiologist needs to perform complex coronary interventions.”
